Insights Into Diffuse Large B-Cell Lymphoma (DLBCL)

Perspectives on drivers in treatment decisions in the management of DLBCL, perception of various therapeutics, and understanding of the current and future treatment landscape

Southwest – February 22, 2021

Faculty Chair

John Burke, MD

Rocky Mountain Cancer Centers, Colorado Springs, CO

Central – April 21, 2021

Faculty Chair

Manali Kamdar, MD

University of Colorado Hospital, Aurora, CO

Midwest – October 7, 2021

Faculty Chair

Matthew Lunning, DO, FACP

University of Nebraska Medical Center, Omaha, NE

More Information

  • Virtual Series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

  • Virtual Series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Virtual Series
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Minnesota, Wisconsin, Michigan, Indiana, Ohio

Example Agenda

Export meeting topics

View Agenda

Example Report

Start discovering the insights

View Report


  • A virtual, moderated roundtable discussion focusing on the treatment of diffuse large b-cell lymphoma (DLBCL)
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: rituximab, lenalidomide, obinutuzumab, idelalisib, bortezomib, ibrutinib, axicabtagene ciloleucel, polatuzumab vedotin


  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors will comprise 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.